Brolucizumab-dbll
Brolucizumab-dbll (pronunciation: bro-lu-ci-zu-mab-dbll) is a biopharmaceutical drug used in the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is a humanized single-chain antibody fragment (scFv) and works by inhibiting vascular endothelial growth factor A (VEGF-A).
Etymology
The name "Brolucizumab-dbll" is derived from the drug's molecular structure. "Brolucizumab" refers to the active ingredient, a monoclonal antibody that inhibits VEGF-A, and "dbll" stands for "double", indicating that the drug contains two linked molecules of brolucizumab.
Pharmacology
Brolucizumab-dbll works by binding to VEGF-A, a protein that promotes the growth of new blood vessels. By inhibiting VEGF-A, the drug helps to slow the progression of nAMD, a condition that can lead to vision loss.
Clinical Use
Brolucizumab-dbll is administered by intravitreal injection, usually once every eight to twelve weeks. It is used in patients with nAMD who have not responded to other treatments.
Side Effects
Common side effects of Brolucizumab-dbll include conjunctival hemorrhage, eye pain, and increased intraocular pressure. In rare cases, the drug can cause serious complications such as retinal detachment or endophthalmitis.
Related Terms
- Monoclonal antibody
- Intravitreal injection
- Vascular endothelial growth factor A
- Neovascular (wet) age-related macular degeneration
- Conjunctival hemorrhage
- Endophthalmitis
- Retinal detachment
External links
- Medical encyclopedia article on Brolucizumab-dbll
- Wikipedia's article - Brolucizumab-dbll
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski